Xianhua Li, Director, on May 13, 2026, sold 1,280,000 shares in Jinkosolar Holding Co. (JKS) for $32,678,400. Following the Form 4 filing with the SEC, Li has control over a total of 10,389,612 ordinary shares of the company, with 10,389,612 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1481513/000110465926061816/xslF345X05/tm2614761-1_4seq1.xml
Wing Keong Siew, Director, on May 13, 2026, sold 16,000 shares in Jinkosolar Holding Co. (JKS) for $417,760. Following the Form 4 filing with the SEC, Siew has control over a total of 186,000 ordinary shares of the company, with 186,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1481513/000110465926061818/xslF345X05/tm2614765-1_4seq1.xml
Mark L Baum, Director and Chief Executive Officer, on May 14, 2026, executed a purchase for 10,000 shares in Harrow (HROW) for $302,000. Following the Form 4 filing with the SEC, Baum has control over a total of 2,996,130 common shares of the company, with 2,996,130 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1360214/000149315226023321/xslF345X05/ownership.xml
John W Kozarich, Director, on May 01, 2026, sold 2,501 shares in Ligand Pharmaceuticals (LGND) for $563,080. Following the Form 4 filing with the SEC, Kozarich has control over a total of 41,786 common shares of the company, with 41,786 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000049/xslF345X05/edgardoc.xml